Seedlabs

Blinded-Rater-as-a-Service for ADHD Intervention Trials

A remote service that provides unbiased expert ratings for ADHD medical trials.

A central, remote outcome-assessment service for ADHD clinical trials: allocation-unaware clinician raters plus a standardized processing-speed task deliver 'probably blinded' endpoints to sponsors, so trial results survive the expectancy effects that inflate unblinded ADHD ratings.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderClinical research services / CRO offerings for CNS and digital-therapeutics trial sponsors.

Concept

A contract research service for sponsors running ADHD intervention trials — drugs, digital therapeutics, devices, and behavioral programs. For each participant, a central pool of trained clinician raters (never on site, never informed of allocation, conducting standardized symptom interviews by video) provides probably-blinded symptom ratings at baseline, endpoint, and follow-up, alongside a short standardized processing-speed task as the objective anchor. Sponsors receive both the central blinded ratings and their sites' usual unblinded ratings, with the divergence quantified as an expectancy-effect readout they can report to regulators and payers. Sold as a fixed per-participant assessment module that drops into any ADHD trial protocol.

Why now

The new meta-analysis demonstrates exactly why this matters: when ADHD outcomes are rated by people probably or certainly unaware of treatment allocation, neurofeedback's apparent benefit vanishes (total symptoms SMD 0.04; inattention SMD 0.04; hyperactivity/impulsivity SMD 0.03 across 19-20 RCTs each), while the one objective measure — processing speed — shows a small real gain (SMD 0.35, k=15, n=909). The companion trial-landscape review quantifies both the addressable market and the pain point: 695 interventional ADHD trials (1999-2021), ~80% non-pharmacological (where blinding is hardest and expectancy effects largest), 212 stimulant interventions, and 31 of 44 pharmacological agents discontinued — meaning sponsors urgently need endpoints that differentiate credibly, and independent probably-blinded raters are the established mechanism for getting them.

Written by GLM · 12 Oct 2026

AI assessment

Backed by 2 papers92

A high-utility, specialized CRO service that solves a specific regulatory pain point (expectancy bias) in ADHD trials using a proven methodological wedge.

Evidence strength
5/5
The idea directly operationalizes the findings of the provided meta-analysis, which explicitly demonstrates the divergence between blinded and unblinded ratings in ADHD interventions.
Market pull
4/5
The high discontinuation rate of pharmacological agents and the prevalence of non-pharmacological trials create a strong incentive for sponsors to use more rigorous, regulator-defensible endpoints.
Novelty & moat
4/5
While other catalog ideas focus on screening or general validation, this is a specific operational service for clinical trial endpoints, filling a gap in trial execution rather than just tool assessment.
Feasibility
5/5
The MVP requires only a network of trained clinicians and a standardized video-interview protocol, making it highly executable without complex R&D.
Wedge clarity
5/5
The 'probably blinded' endpoint module is a sharp, discrete product that can be easily integrated into existing trial protocols as a line item.
Simplicity / focus
5/5
The focus is singular: providing a blinded rating service to eliminate expectancy effects, avoiding the trap of becoming a general-purpose platform.

Scored by Gemma 4 · 12 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Akili Interactivecompany

    Maker of the FDA-cleared EndeavorRx digital therapeutic; its game-based trials are highly expectancy-prone, and probably-blinded central ratings plus a processing-speed anchor would make its endpoints far more credible to regulators and payers.

  • NeuroSigmacompany

    Maker of the FDA-cleared Monarch eTNS System; device trials for ADHD need expectancy-resistant outcome collection, which is precisely what a central blinded-rater module provides.

  • Supernus Pharmaceuticalscompany

    Markets viloxazine (Qelbree), named among the key non-stimulants in the trial landscape; probably-blinded central raters strengthen its ongoing pediatric and adult ADHD trial program against placebo-rating inflation.

  • Takedacompany

    Holds a major ADHD franchise including lisdexamfetamine; credible blinded endpoints reduce the risk that new-indication or comparator trials are confounded by rater expectancy.

  • APSARDorganization

    The American Professional Society of ADHD and Related Disorders could endorse standardized probably-blinded outcome collection as a trial-quality benchmark, giving its members a concrete methodological standard.

Research it builds on

  1. Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials
    Victoria A. Nazarova, Aleksandr V. Sokolov, Vladimir N. Chubarev et al. · 2022 · 108 citations
    All ideas from this paper →
  2. Neurofeedback for Attention-Deficit/Hyperactivity Disorder
    Samuel James Westwood, Pascal-M. Aggensteiner, Anna Kaiser et al. · 2024 · 42 citations
    All ideas from this paper →
Leave feedback
feasibility